Four of six treated adults — 67% — achieved foveal schisis closure at six months in Part B of Atsena’s LIGHTHOUSE trial, a replication rate precise enough to matter: zero of three untreated controls and zero of six untreated contralateral eyes showed the same structural change. That clean internal comparison is doing real scientific work here, functioning as a within-study negative control that substantially tightens the causal inference without requiring a separate placebo arm in the traditional sense.
The pediatric signal is arguably the more consequential result from this readout. Cohort 5 enrolled children aged 8–12, and the safety profile was entirely clear — no serious adverse events, no subretinal deposits, no macular hole formation, no retinal detachment. This matters because XLRS is typically diagnosed in early childhood, meaning the eventual treatment population skews young. Adult safety data alone would leave a gap in the regulatory package that FDA and EMA would eventually demand to fill. Getting clean pediatric data now, concurrent with adult efficacy validation, is efficient trial design. The subretinal deposits seen in a subset of adult Cohort 4 subjects resolved with transient steroids and did not recur in the pediatric cohort — a distinction worth noting as the program moves into 76-patient pivotal enrollment.
Part C, the Phase 3 pivot, is enrolling across North America and Europe with a primary endpoint of microperimetry at 52 weeks — a functional measure of retinal sensitivity that FDA and EMA have both endorsed. That regulatory alignment on a functional rather than purely structural endpoint is not incidental. Microperimetry captures what patients actually experience, and building a BLA around it positions the label to reflect real-world visual benefit rather than anatomical surrogates alone. Enrollment closes Q1 2027 per plan, with BLA submission targeted for 2028. ATSN-201‘s AAV.SPR capsid, designed to spread laterally beyond the subretinal injection bleb without requiring foveal detachment, remains the technical differentiator that makes pediatric administration feasible at all — foveal detachment in a child’s developing retina carries risks that would have constrained any earlier-generation vector.
The single marker to track now is microperimetry consistency between Part A and Part C at the 52-week readout — if the response kinetics that matched across cohorts 1 through 4 hold into the pivotal population, the BLA pathway is essentially de-risked on efficacy grounds.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
